

Organoid-Based Precision Lung Cancer Remodeling


From Static 2D Models to Dynamic 3D Patient Avatars

Chaeuk Chung M.D./Ph.D. | Chungnam National University Hospital

Korean Molecular Lung Cancer Study Group Winter Workshop

Contents

1. The beginning of organoid research
2. Cutting Edge Technology of Organoid
3. Future of organoid





Organoid: Organ + oid (~Resemble Sth)

nature Vol 459 | 14 May 2009 | doi:10.1038/nature07935

LETTERS

Single Lgr5 stem cells build crypt-villus structures *in vitro* without a mesenchymal niche

Toshiro Sato¹, Robert G. Vries¹, Hugo J. Snippert¹, Marc van de Wetering¹, Nick Barker¹, Daniel E. Stange¹, Johan H. van Es¹, Arie Abo², Pekka Kujala³, Peter J. Peters³ & Hans Clevers¹



Organoids recapitulates heterogeneity of organ

nature Vol 459 | 14 May 2009 | doi:10.1038/nature07935

LETTERS

Single Lgr5 stem cells build crypt-villus structures *in vitro* without a mesenchymal niche

Toshiro Sato¹, Robert G. Vries¹, Hugo J. Snippert¹, Marc van de Wetering¹, Nick Barker¹, Daniel E. Stange¹, Johan H. van Es¹, Arie Abo², Pekka Kujala³, Peter J. Peters³ & Hans Clevers¹

nature methods

Explore content ▾ About the journal ▾ Publish with us ▾ Subscribe



[nature](#) > [nature methods](#) > [commentary](#) > article

Commentary | Published: 03 January 2018










Imaging organoids: a bright future ahead

[Anne C Rios](#) ✉ & [Hans Clevers](#) ✉

Nature Methods **15**, 24–26 (2018) | [Cite this article](#)




Organoids: Three-Dimensional Living Models of Human Cell Complexity


	2D Cell Lines	PDX Models	LCO (Organoids)	Visual Proof		
				Organoid	Patient	PDX
Cost	Low	High	Moderate			
Speed	Fast [3-7 days]	Slow [4-8 months]	Moderate [2-4 weeks]			
Heterogeneity Retention	Poor	Good	Good/Polyclonal			
Throughput	High	Low	Moderate/High			

Histological analysis confirms LCOs retain the architectural features of the primary patient tumor.


Organoids: Three-Dimensional Living Models of Human Cell Complexity



2D Cell Culture



Mouse Model



3D Human Lung Organoid


FDA, 식약처도 “마우스 그만” 오가노이드가 바꾼 전임상 지도

☰ Q 서울경제 美 FDA 동물실험 단

미국 식품의약국(FDA)이 의약품 개발 과정에서 동물실험을 단계적으로 폐지하겠다고 선언했지만 국내 산업계는 사실상 무방비 상태다. 관련 법률은 현재 국회에 계류 중으로 통과될 기미가 보이지 않는 상황에서 담당 부처인 식품의약품안전처가 가이드라인을 마련 중이지만 법적 근거가 미비해 산업 육성에는 한계가 있다는 지적이 나온다.

미국 FDA 의약품 동물실험 단계적 폐지 내용	OECD 시험가이드라인으로 승인된 식약처 시험법 목록
오가노이드 독성 테스트와 시계산 모델로 잠재적으로 대체	☑ 유세포 분석을 이용한 피부감작성 시험법
내년부터 비동물 테스트 파일럿 프로그램 시작 목표	☑ 인체각막모델을 이용한 안자극시험법
	☑ 인체전립선암세포주 이용 안드로겐 교란물질 판별시험법
	☑ 인체피부모델을 이용한 피부자극시험법

자료: 식약처







ARTICLE

<https://doi.org/10.1038/s41467-019-11867-6>


OPEN

Patient-derived lung cancer organoids as in vitro cancer models for therapeutic screening

Minsuh Kim¹, Hyemin Mun¹, Chang Oak Sung^{1,2}, Eun Jeong Cho ¹, Hye-Joon Jeon¹, Sung-Min Chun^{1,2}, Da Jung Jung ³, Tae Hoon Shin ³, Gi Seok Jeong³, Dong Kwan Kim⁴, Eun Kyung Choi⁵, Seong-Yun Jeong⁵, Alison M. Taylor⁶, Sejal Jain⁶, Matthew Meyerson ⁶ & Se Jin Jang^{1,2}


Contents

1. The beginning of organoid research
2. Cutting Edge Technology of Organoid
3. Future of organoid



Using patient-derived organoids to predict locally advanced or metastatic lung cancer tumor response: A real-world study

Graphical abstract



Authors

Han-Min Wang, Chan-Yuan Zhang, Kai-Cheng Peng, ..., Hua-Jun Chen, Yi-Long Wu, Jin-Ji Yang

Correspondence

chenhuajun@gdph.org.cn (H.-J.C.), syylwu@live.cn (Y.-L.W.), yangjinji@gdph.org.cn (J.-J.Y.)

In brief

Wang et al. generated lung cancer organoids (LCOs) derived from human malignant serous effusions and tissues. The LCOs accurately represented original tumor features. Drug sensitivity tests were performed to predict clinical response. The results illustrated enormous value of LCO as an *in vitro* platform for personalized medicine of lung cancer.

› Cell Stem Cell. 2025 Aug 7;32(8):1218-1234.e7. doi: 10.1016/j.stem.2025.05.011. Epub 2025 Jun 12.

An organoid co-culture model for probing systemic anti-tumor immunity in lung cancer


Kaiyi Li¹, Chang Liu¹, Xizhao Sui², Chao Li², Ting Zhang¹, Tian Zhao¹, Dong Zhang¹, Hainan Wu³, Yuhan Liu⁴, Shuai Wang⁵, Yingshun Yang⁵, Baobao Lin¹, Wenyan Wang⁶, Fan Yang⁷, Xiaofang Chen⁸, Peng Liu⁹

Affiliations + expand

PMID: 40513558 DOI: 10.1016/j.stem.2025.05.011

Organoid co-culture model

We established a gel-liquid interface (GLI) co-culture of lung cancer organoids (LCOs) and paired peripheral blood mononuclear cells (PBMCs), featuring with enhanced interactions of immune cells and tumor organoids, to mimic the in vivo systemic anti-tumor immunity induced by immune checkpoint inhibitors (ICI).





Lung tumouroids as a testing platform for precision CAR T cell therapy

Received: 22 November 2024


Accepted: 21 November 2025

Published online: 21 January 2026



 Check for updates

Lukas Ehlen^{1,2,17}, Martí Farrera-Sal^{1,17}, Martin Szyska^{1,15}, Janine Arndt^{1,2}, Simon Schallenberg³, Cedric Scholz¹, Mingxing Yang⁴, Claudia Vollbrecht³, Anna Löwa⁵, Rebecca Friedrich¹, Marco Mai¹, Lena Peter ¹, Samira Picht¹, Sarah Schulenberg¹, Daniel Geray¹, Gabriela Korus^{6,7}, Anke Sommerfeld³, Denise Treue³, Julia Strauchmann⁸, Aron Elsner⁸, Jonas Kath ^{9,10}, Valeria Fernandez Vallone¹¹, Maria Joosten³, Franka Klatter-Schulz ⁶, Ansgar Petersen^{6,7}, Harald Stachelscheid ¹¹, Dimitrios L. Wagner ^{9,10,16}, Claudia Spies², Jens-Carsten Rückert⁸, Andreas C. Hocke ⁵, Julia K. Polansky ^{4,12}, Regina Stark ^{13,15}, Oliver Klein¹⁴ & Michael Schmueck-Henneresse ¹ 



A schematic of the lung TO therapy testing platform



Validation of LCO with multi-omics



CAR T cell-mediated killing of TOs




Lung Cancer Organoid in CNUH




- **#1. Early Lung Cancer Organoid**









- **Long-term Whole Cigarette Smoke Extract (WCSE) Exposure Model**



Establishment and Applications of a Long-term Whole Cigarette Smoke Extract (WCSE) Exposure Model in Human Lung Cells and Organoids




Application




Multi-Dimensional models for investigating Cigarette smoke-induced lung carcinogenesis

Human lung cells


Model validation after cigarette exposure



Omics analysis




Mechanistic Validation




Human Lung organoids


Model validation after cigarette exposure




Omics analysis



TCGA analysis



Mechanistic Validation



Under review

#2. Organoid Biobank



... KBP 5기 인체자원은행 특성화 지원사업 계획 ...

개인 맞춤형 의료 및 신약 스크리닝을 위한 바이오뱅크 플랫폼 구축

특성화 질환 : 간암, 위암, 폐암

거점은행 | 충남대학교병원 인체자원은행 |

협력은행#1 | 세종충남대학교병원 |

협력은행#2 | 건양대학교병원 |



특성화 사업 배경 및 필요성 | 사업의 필요성

질환 중요성

대상질환 난치성 암종 치료
불확실성 극복 필요성

간암, 위암, 폐암
국내 발생률 및 사망률 상위권

임상적 미충족 문제

동일 병기라도
환자별 치료 반응 상이,
진행성 단계에서 예후 불량



해결방안

환자 종양 특성을 재현하는 오가노이드(Organoid) 등
고부가가치 인체자원 확보 필수



오가노이드 Organoid

종양의 유전자 변이·표현형·조직 구조 보존
3차원 배양 모델

표적치료제·면역항암제·세포독성 항암제·병용요법
반응 예측 및 스크리닝 도구로 활용 가능

II 사업수행기관 개요

CNUH BIOBANK

STEP 1

Sampling



- Cryo-biopsy
- 30 cc~50 cc blood
- 흡수

STEP 2


PBMC isolation



- PBMC isolation
- hLO generation
- Tissue cryo-preservation in a LN₂ tank
- RNA
- DNA

STEP 3

Organoids production



- Human lung organoid culture

STEP 4

Quality control



- H&E staining
- IHC
- NGS (exome sequencing)

STEP 5

Preservation



- Lung cancer organoid cryo-preservation in a LN₂ tank



V 기대효과 및 향후 계획

상생협력



- 1 특성화 질환에 대한 공동 운영체계 구축 | 2 특성화 인체자원 임상역학정보 표준화 체계 구축
- 3 인체자원 수집 및 (공동)분양 | 4 인체자원 임상역학정보 수집 및 (공동)분양



- 1 특성화 인체자원 수집 및 (공동)분양
- 2 특성화 인체자원 임상역학정보 수집 및 (공동)분양



- 1 특성화 인체자원 수집 및 (공동)분양
- 2 특성화 인체자원 임상역학정보 수집 및 (공동)분양

산학연



충남대학교



건양대학교



고려대학교 세종캠퍼스



을지대학교



한국화학연구원



한국과학기술원



한국과학기술연구원



한국표준과학연구원



아블바이오



큐로셀






EnhancedBio




비오젠

3D BIO SCIENCE


#3. Organoid 3D holotomography and live imaging



Conventional Workflow of Immunotherapy



Pathologist Examination



항암제명	기분종류	용량	주입빈도
Docetaxel	정맥주사	75mg/m ²	1회/3주
Carboplatin	정맥주사	AUC 2	1회/3주
Paclitaxel	정맥주사	175mg/m ²	1회/3주
Docetaxel	정맥주사	75mg/m ²	1회/3주

항암제명	기분종류	용량	주입빈도
Docetaxel	정맥주사	75mg/m ²	1회/3주
Carboplatin	정맥주사	AUC 2	1회/3주
Paclitaxel	정맥주사	175mg/m ²	1회/3주
Docetaxel	정맥주사	75mg/m ²	1회/3주

검사번호: S18-4341A1-2
 검사명: PD-L1 (spindle) IHC (4+)
 검사일: 2024-09-20
 검사시간: 10:00
 검사장소: 병리과
 검사방법: IHC (4+)
 검사결과: PD-L1 (spindle) IHC (4+)
 검사비율: 90%
 검사일자: 2024-09-20
 검사시간: 10:00
 검사장소: 병리과
 검사방법: IHC (4+)
 검사결과: PD-L1 (spindle) IHC (4+)
 검사비율: 90%

PD-L1 High

Percent of PD-L1 stained viable tumor cells of each intensity	Total (%)			
0	1+	2+	3+	
10	0	80	50	100

Total%: Sum of 1+, 2+ and 3+ entries.
 B. Examine the specimen using the appropriate slide(s).
 Direction the staining pattern of the PD-L1 stained viable tumor cells.
 Interpretation: Stained with differing intensities.
 C. Tumor Associated Invasive Cells.
 Invasive cells: Not identified.
 Comments:

I have reviewed all data contained on this data report form and certify that the data are accurate and complete to the best of my knowledge.

Tx. Decision



Fail... Why?

› [Cancer Res Treat.](#) 2025 Oct 28. doi: 10.4143/crt.2025.548. Online ahead of print.

Predictive Role of Baseline Peripheral Lung SUVmax on PET/CT for Immune-Related Pneumonitis and Adverse Events in Lung Cancer Patients Treated with Immune Checkpoint Inhibitors


Kun Ho Kim ¹, Seong Min Kim ¹, Jeong Eun Lee ², Song Soo Kim ³, Da Hyun Kang ²,
Chaeuk Chung ²

› [Lung Cancer.](#) 2026 Jan:211:108879. doi: 10.1016/j.lungcan.2025.108879. Epub 2025 Dec 13.




Multiomic analysis of treatment-naïve NSCLC before the era of neoadjuvant immunotherapy reveals contrasting immune phenotypes in stage IIIA: node-dominant (T1N2) exhibiting hot versus tumor-dominant (T4N0) cold features

Duk Ki Kim ¹, Yooyoung Chong ², Min-Kyung Yeo ³, Da Hyun Kang ¹, Joo-Eun Lee ⁴,
Hyun-Yi Kim ⁵, Min-Woong Kang ⁶, Chaeuk Chung ⁷


Solution: Live 3D Imaging



Tumor Organoid Microenvironment (TOME)





Real-Time Holotomography of TOME



Result

In vitro Immunotherapy Responses






Unpublished


Result

Deep Learning-Based Single TIL Segmentation



Unlabeled




 **Meta**
Segmentation Anything Model



Labeled



Tumor-TILs Interaction




Unpublished





Result

Validation: Immunophenotypes of TILs

①: ROI Selection




②: Object Segmentation




Holotomography

Fluorescence


3D HT MIP








2D HT



PD-1








Merge



Unpublished

Result

Holotomogram-Based Features for Identifying Immunophenotypes




TILs




in collaboration with prof. 박용근 at KAIST

Unpublished


Morphology-Based Immunophenotyping










Quantitative Features of TOILs




Morphology-Based Biomarkers of ICI Response




Morphomics & scRNAseq



#3. Validation of Organoid by 3D Morphomics




Why Validation of Lung Cancer Organoids Matters




Results from unvalidated lung cancer organoids are unreliable.
There is no way to monitor organoid status in real time.
Once sent for NGS or scRNA-seq, the organoids are destroyed.

AI-Driven Organoid Analysis from Live 3D Imaging

Suboptimal enrichment of malignant cells
Dynamic cellular and genetic alterations





Organoid scRNA sequencing



Q. How can we monitor the state of organoids in real time?

Live image, No labeling
3D image



Development of an AI-Based Platform for Lung Cancer Organoid Multi-Omics and 3D Imaging Big Data

Lung cancer organoid Bank

Clinical database
 Pathology, Stage, Genetic profile,
 Target therapy, Immunotherapy,
 Response, Adverse event

Validated organoid
 -100% cancer, 100% normal cell
 -Mixed organoid

Labeled big data

3D holotomography
 Holotomography, LNO421 Monoculture, Cytoplasm, Nucleus, Mitochondria

Multomics data
 Tissue hybridization and RNA barcoding, Cell type annotation, Gene expression analysis

Spatial genomics
 Organoid tissue section, Array of spatially barcoded primers


	3D image	Multi-omics	Spatial genomics
1			
2			
3			
4			
5			
6			
7			
8			
9			
10			
11			
12			

Supervised learning
 CNN-based
 Deep learning






AI assisted
 Organoid Analyzer


Bank of Organoid 3D images




Organoid Characterizing by 3D holotomography



AI Automatically Analyzes Organoid Characteristics from Real-Time, No-Label, Live 3D Imaging




#4. Modeling Drug and Radiation Resistance with Patient-Derived Organoids




Establishment and multi-faceted comparative analysis of acquired resistance organoid models

Establish of Acquired Resistance Organoids




Comparative Analysis




2025년도 대한 결핵 및 호흡기 학회
산하 분자 폐암 연구회 연구 과제


환자유래 폐암 오가노이드를 활용한 약물 내성 지속세포 상태 모델링
및 EGFR 변이 폐암의 3세대 EGFR-TKI 내성 기전 규명 및 극복



3rd Generation EGFR-TKI tolerant persistent LCO



폐암 오가노이드 Drug Tolerant Persister 구축 및 3세대 EGFR TKI 내성 기전 규명 및 극복





기대 효과

3세대 EGFR-TKI 내성 기전 규명 및 극복 타겟 발굴
제약 회사 약물 스크리닝 후보물질 선정


Osimertinib, Lazertinib 약제별 내성 발생 시점 및 내성 기전 규명
환자 맞춤형 약제 선정 근거 제시

3rd Generation EGFR-TKI resistant LCO




	Osimertinib		Lazertinib	
	LogIC50	IC50	LogIC50	IC50
SB#232-2	1.155	14.28	0.8560	7.178
SB#504	1.147	14.03	1.087	12.21
SB#268	0.9364	8.637	0.8663	7.351
PE#2	1.172	14.85	0.8642	7.315
PE#16	1.038	10.91	0.8367	6.866

3rd Generation EGFR-TKI resistant PDOX mouse



Patient-Derived Organoid Xenograft




Contents

1. The beginning of organoid research
2. Cutting Edge Technology of Organoid
3. Future of organoid



#1. 3D printed breathable lung model (BIO-Chip)




#1. Collaboration with Bio-chip

Overview of breathable lung model


제조공정 개발

[잉크젯 기반 폐모델 제작]



[초음파를 이용한 잉크물성 조절]


[얇은 생체막 제작]



Macromol. Biosci., 2023


질병모델링 및 약물 평가

[바이러스]




Biomaterials., 2024

[흡입독성평가]



생체환경 재현 시스템


[혈류 재현 칩]



ACS Biomater. Sci. Eng., 2023


POSTECH

[호흡운동 재현 챔버]




센서통합 스마트 체외모델

[장벽저항 센서]



Biomaterials, 2025


[호흡운동 센서]




BiPP

Mechanical stretch modulate physiology & pathophysiology


3D in vitro Breathable lung model




Breathing dynamics affect cellular property



Virus infection and drug efficacy test




Disease model (Cancer)



Development scaffold for breathable lung model

➤ Fabrication of stretchable hydrogel membrane

Materials for hydrogel membrane




Gelatin methacryloyl (GeIMA)

- Bio compatible
- Stretchable



High surface tension




Acrylamide (AAM)

- Reduce surface tension



Low surface tension

Surface tension assisted manufacturing




GelMA + AAm




3D bioprinting of lung model on the hydrogel membrane

➤ Fabrication process of printed lung model










➤ Characterization of histological property



Our lung model has **thin three-layer structure** by using 3D bioprinting.

Reproduction of physiological breathing mechanics



➤ Breathable chamber



A stretchable lung model was cultured in a breathable chamber capable of applying **negative pressure and air-exposed conditions** to reproduce human lung physiological environment.

Reproduction of physiological breathing mechanics

➤ Lung model mechanical property analysis




Breathing mechanics mimetic chamber **reproduce various breathing dynamics** and allows for the observation of tissue movement in response to internal chamber pressure.

➤ Dynamics of breathing


Sleep

- ΔS 10%
- 8 BPM




Sleep

- ΔS 10%
- 12 BPM





Exercise

- ΔS 20%
- 30 BPM



#2. Digital Twin (Digital Organoid)



System biology leveraging computational modeling and digital twins to understand and interact with complex biological systems

AlphaFold

AlphaFold
Protein Structure Database

[Home](#) [About](#) [FAQs](#) [Downloads](#) [API](#)


AlphaFold Protein Structure Database

Developed by Google DeepMind and EMBL-EBI

Search for protein, gene, UniProt accession or orgar

Search

Examples:




A Digital Twin Platform Based on a lung cancer

최종목표

폐암 디지털 트윈 플랫폼(Omega Twin)을 기반으로 항암제 효과를 정밀 예측하여, 신약 스크리닝과 임상시험 성공률을 높이고 환자 맞춤형 정밀의료에 활용하고자 함.

수술/생검 종양조직 유래
폐암 오가노이드, 공배양
시스템




Omega-Twin

종양오가노이드 미세환경
디지털트윈 시뮬레이션




치료 타겟 발굴, 신약 스크리닝
예상 반응률 기반 맞춤처방



OMEGA: Organoid-based Microenvironment-Embedded Graph-AI architecture for Drug Evaluation

연구요약

Translational Research (From Bed to Bench to Digital, and Back to Bed)




Phorbol 12-myristate 13-acetate (PMA) treatment for 24h, 48h, and 72h. The figure shows a histological section of a tumor organoid with a legend for Phorbol 12-myristate 13-acetate (PMA) treatment and a table of results.

Case #	PMA	Regimen history	Clinical outcome
W01	40%	None/None	PR
W02	100%	None	N/A
W03	0	Docetaxel/None	PD
W04	10%	None/None	PD


폐암 디지털 트윈 플랫폼 (Omega Digital Twin)

Organoid-based Microenvironment-Embedded Graph-AI architecture for Drug Evaluation




Bench to Digital (Omega Twin)

종양오가노이드 미세환경 다중이미지 데이터




세포 개별 레이아웃


세포 분별 3차원 홀로토포그램




다차원 멀티오믹스 데이터




유전자 조절 네트워크
수학적 모델링






디지털 트윈 공간 매핑




From Digital to Bench (Drug screening) & Bed (Precision medicine)




디지털 트윈 기반 항암제 반응성 예측 모델 리포트



임상 데이터 베이스



치료 전 치료 후



Case #	PD-L1	Regimen history	Clinical outcome
#013	40%	Nivo+Xelox	PR
#025	100%	Naive	N/A
#006	0	Atezolizumab	PD
#021	10%	Nivo+Xelox	PD

Take Home Message

1. Organoid-Based Precision Lung Cancer Remodeling and Limitations

- *Validation of lung cancer organoids (LCOs) using multi-omics approaches and co-culture systems with immune cells and CAR-T cells*

2. Cigarette Smoke–Induced Lung Carcinogenesis Model in Lung Organoids

3. 3D Holotomography for Visualization of Cellular Events and Components

- *Comprehensive 3D imaging of dynamic cellular events and structural components*

4. Morphomics-Based Prediction of Immune Cell and LCO Characteristics

5. Modeling Drug and Radiation Resistance Using Patient-Derived Organoids

6. Integration of Lung Cancer Organoids with Breathable Bio-Chips and Digital Twin Platforms

Thank you for your attention

Acknowledgement

연구중심병원육성(R&D)사업



Memorial Sloan Kettering
Cancer Center
(Dr. Joo-Hyeon Lee)

GIST (Jinwook Choi)

KAIST (Yong Ken Park)
KAIST (Jeong Seok Lee)
KAIST (Jong Eun Park)

글로벌 의사과학자
육성사업 (리더)

